POMDOCTOR LIMITED Announces Receipt of Nasdaq Notice
Rhea-AI Summary
POMDOCTOR LIMITED (NASDAQ: POM) received a Nasdaq Deficiency Letter dated Jan 29, 2026, reporting the ADS closing bid price was below the required $1.00 minimum for 33 consecutive business days. The letter currently does not affect listing or trading.
The company has a 180-calendar-day compliance period ending July 28, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days; Nasdaq may grant additional time at its discretion.
Positive
- ADSs remain listed and tradable while the Deficiency Letter has no current effect
- Company granted a 180-calendar-day compliance period through July 28, 2026
- Regain condition clearly defined: $1.00 closing bid for 10 consecutive business days
Negative
- Closing bid below $1.00 for 33 consecutive business days
- Company faces potential Nasdaq compliance risk if not regained by July 28, 2026
- Possible further review or delisting proceedings if Nasdaq does not grant additional time
News Market Reaction – POM
In the Feb 2 session, POM gained 5.15%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.3% during that session. Argus tracked a trough of -11.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.7x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Strategic partnerships | Positive | -1.7% | Strengthened collaborations with domestic pharma firms for internet hospital growth. |
| Dec 03 | Earnings update | Positive | +5.4% | First-half 2025 results with revenue and gross profit growth despite net loss. |
| Oct 10 | Overallotment exercise | Positive | +1.1% | Full exercise of underwriter’s option to buy additional ADSs at IPO price. |
| Oct 09 | IPO completion | Positive | +18.4% | Closing of initial public offering of ADSs on Nasdaq Global Market. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Most prior corporate and financing announcements saw price moves align with the news tone, though the recent strategic partnership update drew a modestly negative reaction despite constructive language.
Over the past few months, Pomdoctor listed on Nasdaq and completed its IPO, including full exercise of the underwriter’s over-allotment, raising gross proceeds of about $23,000,016. Subsequent earnings for the first half of fiscal 2025 showed 16.2% net revenue growth and continued net losses, while cash remained limited. A January 2026-01-16 update emphasized deepening partnerships with pharmaceutical companies to grow its internet hospital business. Today’s Nasdaq minimum-bid-price deficiency notice follows this trajectory of operational progress alongside significant share price pressure.
Key Terms
nasdaq listing rule 5450(a)(1) regulatory
minimum bid price regulatory
compliance period regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until July 28, 2026 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price of the Company's ADSs is at least
In the event the Company does not regain compliance by July 28, 2026, subject to the determination by the staff of Nasdaq, the Company may be eligible for additional time.
The Deficiency Letter will have no effect on the Company's business operations, and the Company will take all reasonable measures to regain compliance.
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-receipt-of-nasdaq-notice-302674985.html
SOURCE POMDOCTOR LIMITED